News

Haggling about location ended
Enlarge image

PoliticsEUFranceGermanyUK

Haggling about location ended

03.07.2012 - No chunks for noone, nuggets for Paris, London and Munich. The EU commission finally agreed on the setting for the proposed EU patents court.

On 29 June at the European Council in Brussels, Belgium, the EU heads of state agreed on a plan to implement a so far only proposed EU patents court which now could become functional in 2014. Currently, the European Patent Office (EPO) has responsibility for the examination and grant of 'European' patents, but once those patents are granted they become an individual patent in each country selected by the proprietor. Should the proprietors of the patents wish to enforce them they must do so in each country individually. The new court will maintain divisions in three different countries with France coming up with the most important one. The central division of the Court of First Instance (CFI) of the Unified Patent Court (UPC) will be - together with the CFI-president's office in Paris. Subdivisions handling chemistry and pharmaceutics industry as well as mechanical engineering will be installed in London and Munich, respectfully. Although Munich has already the headquarters of the EPO the heavy lobbying for Munich as the place for a EU patents court did not suceed in the end.

The long awaited EU patents court will facilitate the introduction of patents with a unitary effect across the member states. However, Italy and Spain are excluded so far because they diagree with the current language arrangements. Uninvolved of the patents court agreement the unitary patent itself has to be approved by the European Parliament and the Council of Ministers. The crucial step is the vote in the parliament on 3 and 4 July. The then following Council approval is merely a formality.

http://www.european-biotechnology-news.com/news/news/2012-03/haggling-about-location-ended.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR32.3%
  • ADDEX3.44 CHF7.8%
  • HBM86.00 CHF4.4%

FLOP

  • PAION2.19 EUR-32.8%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-25.0%

TOP

  • SANTHERA82.00 CHF2184.1%
  • CO.DON2.82 EUR200.0%
  • PAION2.19 EUR157.6%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 22.10.2014